4 research outputs found
Deployable Optical Receiver Array Cubesat
Small satellites and cubesats often have low data transmission rates due to the use of low-gain radio links in UHF and S bands. These links typically provide up to only 1 Mbps for communication between the ground and LEO, limiting the applications and mission operations of small satellites. Optical communication technology can enable much higher data rates and is rapidly gaining hold for larger satellites, including for crosslinks within SpaceX’s Starlink constellation and upcoming NASA deep space missions. However, it has been difficult to implement on small satellites and cubesats due to the need for precision pointing on the order of arcseconds to align the narrow optical laser beam between terminals--a laser transmitter in LEO may yield a footprint less than 100 meters wide at its receiving ground station. We report the development of a 3U cubesat to demonstrate new optical communication technology that eliminates precision pointing accuracy requirements on the host spacecraft. The deployable optical receiver aperture (DORA) aims to demonstrate 1 Gbps data rates over distances of thousands of kilometers. DORA requires an easily accommodated host pointing accuracy of only 10 degrees with minimal stability, allowing the primary mission to continue without reorienting to communicate and/or enabling small satellite missions using low-cost off-the-shelf ADCS systems. To achieve this performance, DORA replaces the traditional receiving telescope on the spacecraft with a collection of wide-angle photodiodes that can identify the angle of arrival for incoming communication lasers and steer the onboard transmitting laser in the corresponding direction. This work is motivated by NASA’s plans for a lunar communications and navigation network and supported by NASA’s Space Technology Program (STP). It is ideally suited for crosslink communications among small spacecraft, especially for those forming a swarm and/or a constellation, and for surface to orbit communications. We will implement the deployable optical receiver aperture and miniature transmission telescope as a 1U payload in the 3U cubesat and conduct the demonstration flight in LEO. Future implementations of the DORA technology are expected to further enable omnidirectional receiving of multiple optical communications simultaneously and accommodate multiple transmitting modules on a single cubesat
Análisis de conglomerados para la segmentación de mercados (Cluster Analysis for Market Segmentation)
Combined effects of temperature and salinity on the demographic response of Proales similis (Beauchamp, 1907) and Brachionus plicatilis (Müller, 1786) (Rotifera) to mercury
Recommended from our members
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with COVID-19.
In this multinational, double-blind, randomised, placebo-controlled, clinical trial (Therapeutics for Inpatients with COVID-19 [TICO]), adults (aged ≥18 years) hospitalised with COVID-19 at 43 hospitals in the USA, Denmark, Switzerland, and Poland were recruited. Patients were eligible if they had laboratory-confirmed SARS-CoV-2 infection and COVID-19 symptoms for up to 12 days. Using a web-based application, participants were randomly assigned (2:1:2:1), stratified by trial site pharmacy, to sotrovimab 500 mg, matching placebo for sotrovimab, BRII-196 1000 mg plus BRII-198 1000 mg, or matching placebo for BRII-196 plus BRII-198, in addition to standard of care. Each study product was administered as a single dose given intravenously over 60 min. The concurrent placebo groups were pooled for analyses. The primary outcome was time to sustained clinical recovery, defined as discharge from the hospital to home and remaining at home for 14 consecutive days, up to day 90 after randomisation. Interim futility analyses were based on two seven-category ordinal outcome scales on day 5 that measured pulmonary status and extrapulmonary complications of COVID-19. The safety outcome was a composite of death, serious adverse events, incident organ failure, and serious coinfection up to day 90 after randomisation. Efficacy and safety outcomes were assessed in the modified intention-to-treat population, defined as all patients randomly assigned to treatment who started the study infusion. This study is registered with ClinicalTrials.gov, NCT04501978.
Between Dec 16, 2020, and March 1, 2021, 546 patients were enrolled and randomly assigned to sotrovimab (n=184), BRII-196 plus BRII-198 (n=183), or placebo (n=179), of whom 536 received part or all of their assigned study drug (sotrovimab n=182, BRII-196 plus BRII-198 n=176, or placebo n=178; median age of 60 years [IQR 50–72], 228 [43%] patients were female and 308 [57%] were male). At this point, enrolment was halted on the basis of the interim futility analysis. At day 5, neither the sotrovimab group nor the BRII-196 plus BRII-198 group had significantly higher odds of more favourable outcomes than the placebo group on either the pulmonary scale (adjusted odds ratio sotrovimab 1·07 [95% CI 0·74–1·56]; BRII-196 plus BRII-198 0·98 [95% CI 0·67–1·43]) or the pulmonary-plus complications scale (sotrovimab 1·08 [0·74–1·58]; BRII-196 plus BRII-198 1·00 [0·68–1·46]). By day 90, sustained clinical recovery was seen in 151 (85%) patients in the placebo group compared with 160 (88%) in the sotrovimab group (adjusted rate ratio 1·12 [95% CI 0·91–1·37]) and 155 (88%) in the BRII-196 plus BRII-198 group (1·08 [0·88–1·32]). The composite safety outcome up to day 90 was met by 48 (27%) patients in the placebo group, 42 (23%) in the sotrovimab group, and 45 (26%) in the BRII-196 plus BRII-198 group. 13 (7%) patients in the placebo group, 14 (8%) in the sotrovimab group, and 15 (9%) in the BRII-196 plus BRII-198 group died up to day 90.
Neither sotrovimab nor BRII-196 plus BRII-198 showed efficacy for improving clinical outcomes among adults hospitalised with COVID-19.
US National Institutes of Health and Operation Warp Spee